Emily Martin

#Amyloidosis researcher interested in pan-amyloid imaging and immunotherapy; early detection enthusiast; patient support group facilitator

[Attralus @attralus]

@Bayer to expand into molecular imaging with acquisition of innovative pan-amyloid radiotracers from Attralus. Read the press release: https://t.co/s2LNk5koUE. #amyloidosis

[Attralus @attralus]

Attralus receives Orphan Drug Designation from @US_FDA for AT-02 for the treatment of ATTR #amyloidosis. Read the press release: https://t.co/VsgX7vRZuX

[Ahmad Masri @MasriAhmadMD]

Fantastic work by Jon Wall, @EM4research et al
SPECT & PET tracers have different pros/cons
But this is a definite advancement in the field. Meanwhile, we are starting our REVEAL pIII trial of evuzamitide PET @DorbalaSharmila

#CardioTwitter #CVNuc #ASNC2024

[awechalekar @awechalekar]

@attralus Great news and look forward to the studies of this potentially paradigm changing tracer in amyloid diagnosis and management

[Ahmad Masri @MasriAhmadMD]

Excellent news. I-124 evuzamitide is one of the major and important developments in the systemic amyloidosis space

[Ahmad Masri @MasriAhmadMD]

In case you missed it - a phase III trial of I-124 evuzamitide for the diagnosis of cardiac amyloidosis will kick off in early 2025
#CVNuc #CardioTwitter

[Amyloidosis Research Consortium @Amyloidosis_ARC]

Encouraged that the @US_FDA has recognized the tremendous need and the role that diagnostics can play in improving outcomes for #amyloidosis patients.

⚕️🚨 Physicians: Recruitment of patients w/suspected cardiac amyloidosis in the planned Phase 3 study of AT-01 will be critical!

[Sharmila Dorbala @DorbalaSharmila]

@attralus Congratulations Spencer and Attralus Team! Noninvasive molecular diagnosis of cardiac amyloidosis is crucial for early diagnosis and effective therapy. Excited to serve as PI of the Phase 3 study REVEAL-Research with EVuzamitide to Elucidate cardiac AmyLoidosis.

[Attralus @attralus]

Attralus is excited to announce that we have received Breakthrough Therapy Designation for our pan-amyloid diagnostic PET imaging candidate I124-evuzamitide (AT-01) for cardiac #amyloidosis. Read the press release: https://t.co/v8FYW4hFOS.

[Emily Martin @EM4research]

@josephobrien200 @bncs_imaging Evaluation of the SPECT tracer is underway! Our initial data from the study was presented at the ACC a few days ago. Exciting!

[Emily Martin @EM4research]

@NotNoninvasive @DorbalaSharmila @ctinocomesquita @MyASNC @estelais @premsoman123 @DrCAkincioglu @SinghVasvi @CookCtyCardio Thank you! Yes, great to connect with you as well!

[Emily Martin @EM4research]

@DorbalaSharmila @ctinocomesquita @MyASNC @estelais Thank you! We are very excited and hopeful that this reagent will be able to help both patients and physicians.

[Emily Martin @EM4research]

@MasriAhmadMD Thanks, Ahmad. We are excited about the potential of this new reagent to help patients!

[Emily Martin @EM4research]

@spencerdguthrie Love it!

[JACC Journals @JACCJournals]

Iodine (124I) evuzamitide is a #ThinkPET #radiotracer for #amyloidosis imaging with high sensitivity. In this #JACCIMG Phase I/II study, there was potential for early, presymptomatic disease detection throughout the body. https://t.co/WstdfXjqg8

#cvPET #cvImaging @EM4Research

[BNCS_imaging @bncs_imaging]

Have you heard of iodine (124I) evuzamitide (124I-P5+14)? Two papers show that this might be the next big thing for the imaging of cardiac amyloidosis.

[SpencerDGuthrie @spencerdguthrie]

Cardiac Amyloid Detection by PET/CT Imaging of Iodine (124I) Evuzamitide in systemic #amyloidosis https://t.co/glx5JWpzci

[Brett Sperry, MD @BrettSperryMD]

Packed house for the @AmyloidosisSupp ATTR meeting in Chicago.

Congrats on another great meeting @MurielFinkel !

[Frontiers - Immunology @FrontImmunol]

New Research: Development and characterization of a prototypic pan-amyloid clearing agent – a novel murine peptide-immunoglobulin fusion: Introduction

Systemic amyloidosis is a progressive disorder characterized by the extracellular… #immunology https://t.co/Rrr6GX7LZt

[Attralus @attralus]

Attralus Announces Presentation of Clinical Data for 124I-Evuzamitide (AT-01), a Novel Amyloid-Specific PET Imaging Agent, at #ASNC2023
Read more - https://t.co/GiNoglS8P9 #amyloidosis